• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What We’re Reading: ADHD Medication Mix-Up; Surge in ACOs; Mifepristone Restrictions


Attention-deficit/hyperactivity disorder (ADHD) medication packets are found with incorrect pills; CMS data reveal record numbers of providers and beneficiaries participating in accountable care organizations (ACOs); Supreme Court will hear arguments over FDA regulations on abortion medication in March.

ADHD Medication Pulled From Shelves Amid Pill Mix-Up

Azurity Pharmaceuticals issued a recall for attention-deficit/hyperactivity disorder (ADHD) medication dextroamphetamine sulfate (Zenzedi) following the discovery of a potential mix-up in pill packaging, according to CNN. Concerns arose when reports surfaced of incorrect pills found in medication packets, prompting the company to take action to prevent any potential health risks. Patients and health care professionals have been urged to check their supplies and contact the company for guidance. A national shortage of ADHD drugs has been ongoing since the fall, leaving some patients unable to secure their needed medications.

Medicare Sees Surge in ACOs, but Challenges Remain

A record-breaking 13.4 million Medicare beneficiaries are now under the care of 122 accountable care organizations (ACOs) in the Realizing Equity, Access, and Community Health (REACH) Model and 481 ACOs in the Medicare Shared Savings Program, according to Axios. In a statement, the National Association of ACOs (NAACOS) applauded the growth facilitated by recent changes to support provider organizations in joining value-based care models. Despite this success, challenges persist, with NAACOS recommending that CMS implement policies to sustain ACO participation.

Supreme Court to Review Mifepristone Restrictions

The US Supreme Court has announced its schedule to review a crucial case regarding mifepristone, a drug used in medication abortions, with arguments slated for late March, according to Stat. The case challenges FDA restrictions that require in-person dispensing, particularly during the COVID-19 pandemic, reigniting the debate on women's access to abortion pills. The outcome of this legal battle is poised to have significant implications for reproductive rights, with potential ramifications for the accessibility of abortion services across the nation.

Related Videos
Ryan Stice, PharmD
Leslie Fish, PharmD.
Ronesh Sinha, MD
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Kimberly Westrich, MA
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Pat Van Burkleo
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
Related Content
© 2024 MJH Life Sciences
All rights reserved.